ABSTRACT
INTRODUCTION
Diabetes is a major health problem in the world, the micro-and macrovascular complications remain a constant challenge to the quality of life as well as increasing morbidity and mortality rate
(1) . Persistent microalbuminuria is an established predictor of diabetic nephropathy leading to progressive renal insufficiency and end-stage renal disease and is associated with an increased risk of cardiovascular disease in patients with both type I and type II diabetes (2-4) . Increasing urinary albumin excretion rate reflects vascular damage in the kidneys as part of systemic endothelial dysfunction (5) . Endothelial dysfunction is the initial step in atherogenesis, which is largely responsible for the development of ischemic heart disease and thrombotic strokes (6) . Subclinical systemic inflammation is involved in the pathogenesis of all stages of atherosclerosis (7) . Low grade elevation of acute phase reactants, proinflammatory cytokines and cell adhesion molecules were shown to be associated with future development of myocardial infarction, stroke and peripheral vascular disease with cardiovascular mortality (8) . Several studies suggest that activation of innate immune system likely to be at least one of common antecedents of both atherosclerosis and type II diabetes. YKL-40 was reported to be a marker of inflammation and endothelial dysfunction (9) . It is produced locally at sites of inflammation, (10) unlikely to Creactive protein produced by liver in response to (11) .
YKL-40, a phylogenetically highly conserved heparin-and chitin-binding lectin without chitinase activity, is a member of the ''mammalian chitinaselike proteins'' (7, (12) (13) (14) . The gene for human YKL-40 is located on chromosome 1q32.1, has a size of 7948 b.p and contains 10 exons (15) . The crystal structure of human YKL-40 protein has been described (16, 17) .The protein has several names: (18) , human cartilage glycoprotein-39 (HC gp39) On the basis of 24-h urine analysis as part of the routine care of the patients, they were divided into; 39 patients with normoalbuminuria (urinary albumin excretion rate <30 mg/24 h), 46 patients with persistent microalbuminuria (at least two of three consecutive urine samples with albumin excretion rate 30-300 mg/24 h), and 40 patients with persistent macroalbuminuria/diabetic nephropathy (albumin excretion rate >300 mg/24 h). Diabetic retinopathy was assessed in all patients by fundus photography after pupillary dilatation and graded as nil, simplex, or proliferative. Control subjects were randomly selected from the general healthy population with matching age and sex. They had no signs or clinical symptoms of cancer, liver, metabolic, endocrinal, cardiovascular, or other systemic diseases. The study was approved by the local ethics committee. Prior to participation all patients and controls gave their informed written consent.
Biochemical analysis
Urinary albumin concentration was measured by Siemens Healthcare Diagnostics Inc., USA, from 24-h urine sample.
Eight ml venous blood sample was drawn, in the morning after overnight fasting (10-12 h), 7 ml on a plain tube and serum was separated after centrifugation at 2500 rpm × 10minutes, then stored frozen at -80 0 C until analysis. 
RESULTS
Clinical and biochemical data for the control group and the diabetic patients differentiated according to level of albuminuria are shown in (Tables 1&2). YKL-40 levels according to level of albuminuria are illustrated in (Fig.1) . Mean YKL-40 levels were highly significantly different among all groups (P < 0.001), with increasing YKL-40 levels with the increase levels of albuminuria. Moreover, pairwise comparisons showed a highly significant difference between each two groups (P < 0.001). Highly significant lower eGFR was found in the micro-and macroalbuminuria groups (P < 0.001, for each group) but no significant difference in normoalbuminuria group (P = 0.456) versus control group. Other pairwise comparisons showed a highly significant difference (P < 0.001).
There was highly significant increase of serum hsCRP in all diabetic groups versus control group (P < 0.001, for each group), while there was no significant difference between microand macroalbuminuria groups (P = 0.058). Also, for HbA 1c there was highly significant increase in each diabetic group versus control group (P < 0.001). No significant difference between microand macroalbuminuria groups was found (P = 0. 469), there was a highly significant increase in both groups versus normoalbuminuria group (P < 0.001).
For insulin resistance expressed as HOMA model there was highly significant increase in all diabetic groups versus control group (P < 0.001 for each group). While, a significant difference between microand macroalbuminuria groups was found (P = 0.006), there was highly significant increase in both groups versus normoalbuminuria group (P < 0.001).
There was highly significant increase of serum TG, total-C and LDL-C in each diabetic group versus control group (P < 0.001), but highly significant decrease of serum HDL-C in the three groups versus control group (P < 0.001).
Regarding diabetic retinopathy, there was no significant difference of YKL-40 levels between the different grades of retinopathy within each diabetic group (P = 0.053, 0.391& 0.859 within normo-, micro-& macroalbuminuria groups respectively) (Table 3) .
Pearson's correlation between YKL 40 levels and different parameters showed correlation of YKL 40 with hsCRP and HOMA-IR (r = 0.746, P < 0.001 & r = 0.792, P < 0.001, respectively) in the total group of participants. But, this correlation was not significant in any of the different subgroups. Significant correlations of YKL-40 were also found with duration of diabetes, Hb A 1C , eGFR (negative correlation), serum creatinine, TG, total-C, HDL-C (negative correlation), LDL-C and urinary albumin in the total group of participants (Table 4) .
The changes by stepwise linear regression analysis showed that, YKL-40 levels were affected by serum TG, eGFR and hsCRP (P =0.005, < 0.001& = 0.045 respectively), but not affected by HOMA-IR (P = 0.192) in the total group of participants (patients & control).
ROC curve was done to discriminate between patients with and without albuminuria, using YKL-40 as a discriminator between both groups. The results showed that, the cut off value of YKL-40 is 87.5 ng/ml (area under the curve = 0.971) with sensitivity 93% and specificity 88% ( Figure 1: Median levels (minimum-maximum) of YKL-40 in the three diabetic groups compared with the control group: 37 (24-55) ng/ml in the control group, 77 (47-105) ng/ml in the normoalbuminuria group, 110 (69-158) ng/ml in the microalbuminuria group, 147 (89-195) ng/ml in the macroalbuminuria group (p < 0.001 for each group Vs control group). 
DISCUSSION
Despite improvement and intensified treatment modalities in diabetic patients, still several researches focus on more depth in the pathogenesis and complications of these patients, looking for new inflammatory markers and cytokines that enhance vascular endothelial dysfunction and its role in subclinical inflammation (27) . YKL-40 has been regarded as an acute phase protein, since it is secreted from a variety of cells involved in infection/inflammation. The participation of YKL-40 in inflammatory states and vascular processes implies that YKL-40 may be elevated in conditions with subclinical inflammation such as type II diabetes and insulin resistance as well as endothelial dysfunction and atherosclerosis (23) . The present study showed that serum YKL-40 levels were elevated in patients with type II diabetes compared to healthy controls, with increasing YKL-40 levels with the increase in the levels of albuminuria. This finding is in agreement with previous studies showing that chronic low-grade inflammation is associated with the occurrence and progression of (micro)albuminuria (28) and that both micro-and macroalbuminuria are accompanied by increased levels of a variety of markers of endothelial dysfunction.
(1) Also, other studies reported that patients with type II diabetes have elevated plasma YKL-40 levels compared to healthy control subjects (23, 29-32 ) . Chronic low-grade inflammation and endothelial dysfunction seem to be closely linked, and it seems that chronic low-grade inflammation can be both a cause and a consequence of endothelial dysfunction. Dysfunction of the vascular endothelium is considered an important factor in the pathogenesis of diabetic micro-and macroangiopathy
(1, 33) . Previous studies showed that YKL-40 plays a role in endothelial dysfunction in relation to cell migration, reorganization, and tissue remodeling during atherogenesis . Also, in the current study marked changes in the lipid profile was found in diabetic patients in the form of increased serum TG, total-C and LDL-C and decrease serum HDL-C in the three diabetic groups compared to the control group, with more dyslipidemic changes in patients with higher levels of albuminuria (macroalbuminuria).This is in accordance with previous studies which reported that diabetic patients with nephropathy have more marked dyslipidemias (particularly low HDL-C and higher triglycerides) (49,50) . An established knowledge about impact role of lipid metabolism in early processing of atherosclerosis is well known. So, dyslipidemia is deleterious especially in diabetic patients (50) . Regarding retinopathy within diabetic patients, the study did not show any association between YKL-40 levels and the severity of retinopathy. This finding is in harmony with the finding of Rathcke et al.
(33) who reached the same results. Diabetic patients especially those with micro and macro albuminuria frequently had higher prevalence of retinopathy as a part of low grade inflammation, endothelial dysfunction, and high evidence of retinal arteries atherosclerotic features. Also, this insignificant association between YKL-40 and the severity of retinopathy even in macroalbuminuria group is most likely to be explained by a systemically accentuated inflammatory state minimizing the individual impact of YKL-40 (33) . Finally, ROC curve analysis showed that, YKL-40 might be a good discriminator between patients with and without albuminuria. This is in accordance with previous studies recorded statistical significant association between YKL-40 and albuminuria in type II diabetic patients and demonstrated that serum YKL-40 level was a determinant of albuminuria independently of conventional risk factors (31, 51) . YKL-40 plays an important role in the process of diabetic nephropathy and atherogenesis via intermediating vascular endothelial dysfunction (51) .
Albuminuria reflects vascular damage in the kidneys as part of systemic endothelial dysfunction (5) . Accordingly, serum YKL-40 level can be a good determinant of albuminuria in type II diabetic patients (31) . In conclusion, YKL-40 has emerged as a promising marker of inflammation and endothelial dysfunction that is involved in the pathogenesis of diabetic micro-and macroangiopathy.
That finding suggests a role for YKL-40 in the gradually progressing vascular complications in patients with diabetes, with YKL-40 being a possible early and good marker of renal affection. It seems to be useful for screening because it is detectable in early stages and subclinical diseases. an independent predictor of ischemic heart disease. Arterioscler. Thromb. Vasc. Biol., 19:1992 -1997 
